Join Prof. Francesco Giorgino and Dr. Erika Bezerra Parente as they identify some takeaways from EASD 2023, including data and discussions on treatment non-adherence, SGLT2 inhibitors, and stigma
For more free education, go to diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn.
Faculty disclosures
Prof. Francesco Giorgino
Grants or contracts: Eli Lilly, Roche Diabetes Care
Consulting: Eli Lilly, Novo Nordisk
Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim
Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune
Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE
Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk
Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi
Dr. Erika Bezerra Parente
Honoraria for lectures, presentations and education events: Sanofi
Funding Information:
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.
Accreditation information
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: None